Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
6. |
ECCT/24/08/04 | WHO A66045 Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Machakos county hospital (Machakos county) 2. Pumwani maternity hospital (Nairobi City county) 3. Kiambu level 5 hospital (Kiambu county) |
View |
7. |
ECCT/24/08/03 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Mary Inziani Matilu Site(s) in Kenya 1. KEMRI-Mtwapa Clinical Annex (Kilifi county) 2. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 3. Clinical Research Health Network (CREA-N) (Machakos county) 4. University of Nairobi Clinical Research Centre (Nairobi City county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
View |
8. |
ECCT/24/08/02 | S4V02 Safety and immunogenicity of a second generation Shigella bioconjugate vaccine: a phase II randomized, controlled, and blinded study in 9-month-old infants |
Principal Investigator(s) 1. Richard Omore Site(s) in Kenya Siaya County Referral Hospital |
View |
9. |
ECCT/24/08/01 | Evaluate clearance of HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Kevin Makori Gesimba Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Victoria Cancer Care and Research centre (Nyamira county) |
View |
10. |
ECCT/24/07/05 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Bernhards Ogutu Site(s) in Kenya 1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county) |
View |